BURLINGTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 10, 2023, to discuss the financial results for the first quarter 2023 and provide a business update.
Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13737717.
To access the new Call me™ feature, which avoids having to wait for an operator, click here.
The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7578
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.48 |
| Daily Change: | 0.40 9.80 |
| Daily Volume: | 424,499 |
| Market Cap: | US$236.500M |
May 14, 2025 March 19, 2025 February 05, 2025 January 10, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
